|
We asked 40 pharma leaders, compared with 2011, has your company attended more or fewer conferences and exhibitions?
| More |
33% |
| Les |
67% |
| About the same |
0% |
 |
|
|
|
|
|
|
|
20 November, 2012
|
| In this Issue |
 |
Blockbuster Era May Be in Decline… But it's Not Over Yet
In this video, Senior Editor Ben Comer offers a preview of Pharm Exec's upcoming 2012 Pipeline Report, and reveals that many of this year's featured companies are still anticipating billion-dollar sales... View the video |
European Pharma Bets on Greek Salvation
Reflector points to the obvious and subtle flaws in the European Federation of Pharmaceutical Industries and Associations' recent offer to Greece of a EUR2.8 billion cap of drug spending... Read more |
Pharma 2020 Forecast: Cold Comfort
PwC's new Pharma 2020 report is a mixture of gloomy and glowing scenarios. On the one hand, innovations in other areas such as mobile technology promise to breathe new life into pharma with cutting-edge initiatives. On the other, stark fiscal realities and the coupling of stale R&D methodologies to an antiquated managerial culture suggest a dire need for company reinvention... Read more |
Read the New Pharm Exec Global Digest
This month's issue: how John Dalli's abrupt departure points to an EC regulation crisis; how Denmark's Lundbeck is taking on America; brand development in a post-digital world; Takeda's plans for BRIC ... Read more
|
Why Do So Many New Drugs End Up as Launch Failures?
Pharm Exec's new iPad edition eBook, Global Launch in a Post-blockbuster Era, is available for download now... Read more
|
|
 |
|
|
